Consequently, combining nucleolin inhibitor (aptamer AS1411) with doxorubicin greatly reduces the survival chance of DLBCL cells by compromising DNA repair capabilities provided by TopIIA. Here, NUCLEOLIN is linked to diffuse large B-cell lymphoma.